The study is to assess the safety and possible efficacy of umbilical cord blood mononuclear cells (UCBMC) treatment of chronic ischemic stroke.

This is an open-label, delayed-treatment trial.

A total of 12 subjects fulfill the inclusion and exclusion criteria will be recruited and randomly assigned into two treatment group. Group A (early-treatment group) will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0. Group B (delayed-treatment group) will participate in 6 months observation before the UCBMC transplantation at Month 6. All subjects will be followed up for 18 months from enrollment at Day 0. Long-term follow-up will be carried up to 36 months if applicable.

The adverse events and safety parameters will be collected and recorded. In addition, the stroke scores , gait and brain MRI will be obtained before and after the treatment to assess the safety and potential treatment effect of UCBMC in chronic ischemic stroke.

Inclusion Criteria:

• either gender, age 35 -65 years old;
• ischemic stroke > 6 months and < 60 months;
• stable hemiplegia or hemiparesis condition > 3 months;
• stroke-induced clinical deficits affecting motor, perceptual, or language functions, with NIHSS of 5-15;
• stroke in the middle cerebral artery territory;
• subjects able to understand, sign and date the informed consent form

Exclusion Criteria:

• non-ischemic mechanism, subarachnoid hemorrhage, primary intracerebral or intraventricular hemorrhage;
• pregnant or lactating women;
• alcohol or drug abuse in previous 3 months;
• significant medical diseases or infections;
• current participation in another investigational study or taking any investigational drug within last 4 weeks before the screening;
• unavailability of HLA-matched umbilical cord blood unit;
• investigator suggests that the subject would not suitable to perform the surgery or participate in the study